aspirin has been researched along with Pregnancy in Diabetes in 20 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes." | 9.05 | The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020) |
| "This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus." | 8.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| "Whether low-dose aspirin prevents preeclampsia is unclear." | 6.69 | Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998) |
| "Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality." | 5.72 | Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022) |
| "This was a prospective observation of pregnancy outcomes among 462 women with pregestational diabetes mellitus (White classes B-F) and singleton pregnancies who were enrolled in a multicenter trial to compare low-dose aspirin with placebo for preeclampsia prevention." | 5.09 | Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; MacPherson, C; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, BM; Thurnau, G; VanDorsten, JP, 2000) |
| "We studied 2503 women with either diabetes mellitus, chronic hypertension, multifetal gestation, or pre-eclampsia in a previous pregnancy who participated in a multicenter study comparing aspirin and placebo in preventing pre-eclampsia." | 5.08 | Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Dombrowski, M; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, M; McNellis, D; Meis, P; Miodovnik, M; Paul, R; Roberts, J; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998) |
| " Over the past three decades, studies have investigated the role of aspirin in preeclampsia prevention, yielding some promising results for certain at-risk groups, yet unconvincing evidence of benefit among women with pre-pregnancy diabetes." | 5.05 | The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes. ( Breathnach, FM; Finnegan, C, 2020) |
| "This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus." | 4.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| "Aspirin was significantly associated with a higher birthweight Z-score (0." | 2.84 | Impact of aspirin on fetal growth in diabetic pregnancies according to White classification. ( Adkins, K; Allshouse, AA; Heyborne, KD; Metz, TD, 2017) |
| "Whether low-dose aspirin prevents preeclampsia is unclear." | 2.69 | Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. ( Caritis, S; Hauth, J; Klebanoff, M; Landon, M; Lindheimer, MD; Meis, P; Miodovnik, M; Paul, R; Sibai, B; Thom, E; Thurnau, G; VanDorsten, P, 1998) |
| "Preeclampsia is a multisystem disorder that complicates 6% to 8% of pregnancies, with higher rates in women with preexisting hypertension, diabetes mellitus, or previous history of preeclampsia." | 2.42 | What we have learned about preeclampsia. ( Caritis, S; Hauth, J; Sibai, BM, 2003) |
| "Insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE) are two common autoimmune disorders that affect women of childbearing age." | 2.39 | Nutritional consequences of chronic maternal conditions during pregnancy and lactation: lupus and diabetes. ( Ferris, AM; Reece, EA, 1994) |
| "Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality." | 1.72 | Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. ( Olson, DN; Ranzini, AC; Russell, T, 2022) |
| "Dyslipidemia is associated with macular exudates and vision loss." | 1.32 | Preventing diabetic retinopathy through control of systemic factors. ( Fong, D; Jain, A; Sarraf, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 7 (35.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ray, JG | 2 |
| Abdulaziz, KE | 1 |
| Berger, H | 1 |
| Olson, DN | 1 |
| Russell, T | 1 |
| Ranzini, AC | 1 |
| Bruno, AM | 1 |
| Allshouse, AA | 2 |
| Metz, TD | 2 |
| Theilen, LH | 1 |
| Ramlakhan, KP | 1 |
| Johnson, MR | 1 |
| Roos-Hesselink, JW | 1 |
| Hameed, AB | 1 |
| Combs, CA | 1 |
| Finnegan, C | 1 |
| Breathnach, FM | 1 |
| Adkins, K | 1 |
| Heyborne, KD | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| Liew, A | 1 |
| McGurk, C | 1 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Smyth, A | 1 |
| Todd, M | 1 |
| Tuthill, A | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Bartsch, E | 1 |
| Medcalf, KE | 1 |
| Park, AL | 1 |
| Sibai, BM | 2 |
| Caritis, S | 4 |
| Hauth, J | 4 |
| Jain, A | 1 |
| Sarraf, D | 1 |
| Fong, D | 1 |
| Valone, J | 1 |
| Tunbridge, RD | 1 |
| Ferris, AM | 1 |
| Reece, EA | 1 |
| Sibai, B | 2 |
| Lindheimer, MD | 1 |
| Klebanoff, M | 3 |
| Thom, E | 2 |
| VanDorsten, P | 2 |
| Landon, M | 3 |
| Paul, R | 3 |
| Miodovnik, M | 3 |
| Meis, P | 3 |
| Thurnau, G | 3 |
| Lindheimer, M | 2 |
| Dombrowski, M | 2 |
| McNellis, D | 2 |
| Roberts, J | 2 |
| Rai, R | 1 |
| Regan, L | 1 |
| VanDorsten, JP | 1 |
| MacPherson, C | 1 |
| Nanda, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Assessment of the Cardiovascular Risk Profile of Infants Exposed to Pre-eclampsia in Utero[NCT05091827] | 234 participants (Anticipated) | Observational | 2021-11-30 | Not yet recruiting | |||
| Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy[NCT00287651] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Administrative) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for aspirin and Pregnancy in Diabetes
| Article | Year |
|---|---|
Pregnancy and cardiovascular disease.
Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin; | 2020 |
The Role of Aspirin for Preeclampsia Prevention in Women with Diabetes.
Topics: Aspirin; Diabetes Mellitus, Type 2; Female; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; | 2020 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.
Topics: Aspirin; Body Mass Index; Chronic Disease; Cohort Studies; Early Diagnosis; Female; Humans; Hyperten | 2016 |
What we have learned about preeclampsia.
Topics: Aspirin; Female; Gestational Age; Humans; National Institutes of Health (U.S.); Platelet Aggregation | 2003 |
Proliferative diabetic retinopathy and patient age: presentation, prognosis, and management.
Topics: Adolescent; Adult; Age Factors; Anticoagulants; Aspirin; Diabetes Mellitus, Type 1; Diabetic Retinop | 1984 |
The management of pregnancy in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Congenital Abnormalities; Female; Humans; H | 1994 |
Nutritional consequences of chronic maternal conditions during pregnancy and lactation: lupus and diabetes.
Topics: Adult; Aspirin; Autoimmune Diseases; Diabetes Mellitus, Type 1; Female; Humans; Lactation Disorders; | 1994 |
Antiphospholipid syndrome and pregnancy loss.
Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndro | 1998 |
4 trials available for aspirin and Pregnancy in Diabetes
| Article | Year |
|---|---|
Impact of aspirin on fetal growth in diabetic pregnancies according to White classification.
Topics: Adult; Aspirin; Birth Weight; Female; Fetal Development; Fetal Macrosomia; Humans; Infant, Newborn; | 2017 |
Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Adult; Aspirin; Chronic Disease; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hyp | 1998 |
Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Adult; Aspirin; Blood Pressure; Female; Gestational Age; Humans; Hypertension; Parity; Placebos; Pre | 1998 |
Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
Topics: Aspirin; Birth Weight; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; | 2000 |
8 other studies available for aspirin and Pregnancy in Diabetes
| Article | Year |
|---|---|
Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and Hypertension.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Hypertension; Length of Stay; Obesity; Pre-Eclampsia; Pr | 2022 |
Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence.
Topics: Aspirin; Autoimmune Diseases; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Pre- | 2022 |
Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus.
Topics: Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension, Pregnancy-Induced | 2023 |
Society for Maternal-Fetal Medicine Special Statement: Updated checklist for antepartum care of pregestational diabetes mellitus.
Topics: Aspirin; Checklist; Delivery, Obstetric; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disea | 2020 |
ACOG Practice Bulletin No. 201 Summary: Pregestational Diabetes Mellitus.
Topics: Administration, Oral; Aspirin; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2018 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
Preventing diabetic retinopathy through control of systemic factors.
Topics: Anticoagulants; Aspirin; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Female; G | 2003 |
Teratogenic effects of environmental agents on embryonic development.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Anti-Bacterial Agents; Anticonvulsants; Antide | 1975 |